DMRA
Galecto, Inc. NASDAQ$25.93
Mkt Cap $1.6B
52w Low $2.45
65.4% of range
52w High $38.33
50d MA $26.14
200d MA $17.12
P/E (TTM)
-0.2x
EV/EBITDA
1.1x
P/B
0.1x
Debt/Equity
0.0x
ROE
-87.3%
P/FCF
-4.3x
RSI (14)
—
ATR (14)
—
Beta
1.60
50d MA
$26.14
200d MA
$17.12
Avg Volume
302.4K
About
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi,…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.14 | -3.24 | -2216.4% | 21.15 | -0.1% | -9.2% | -14.2% | +9.0% | +13.1% | +18.4% | +25.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | RBC Capital | Initiates | Outperform | $40 | $25.42 | $25.85 | +1.7% | -2.6% | +0.3% | -4.7% | -5.9% | +0.9% |
| Feb 17 | Guggenheim | Maintains | Buy → Buy | — | $29.12 | $30.52 | +4.8% | +2.7% | +4.7% | +4.6% | +3.0% | +2.3% |
| Dec 8 | Guggenheim | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
Recent Filings
8-K · 4.01
!!! Very High
Damora Therapeutics, Inc. -- 8-K 4.01: Auditor Change / Resignation
Damora Therapeutics dismissed EY Denmark as its auditor on April 17, 2026, which may signal accounting disagreements or cost concerns and could raise investor questions about financial reporting reliability.
Apr 20
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A life sciences-focused executive with deep investment banking expertise joined one of these companies, potentially signaling strategic M&A activity or capital-raising plans ahead.
Mar 23
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
The company is rebranding with a new name and ticker symbol, signaling a strategic repositioning that investors should monitor for potential business model changes or market perception shifts.
Mar 10
8-K
Damora Therapeutics, Inc. -- 8-K Filing
Damora Therapeutics completed its public offering on February 12, 2026, following SEC filing of final prospectus supplement terms on February 11, 2026.
Feb 11
8-K
Damora Therapeutics, Inc. -- 8-K Filing
Damora Therapeutics appointed COO Sherwin Sattarzadeh as interim principal executive officer, signaling leadership transition that may indicate CEO departure and potential uncertainty about executive stability.
Feb 10
Data updated apr 25, 2026 5:28am
· Source: massive.com